Lifeboat Foundation

Advanced glycation end products (AGEs) accumulate in the brain, leading to neurodegenerative conditions such as Alzheimer’s disease (AD). The pathophysiology of AD is influenced by receptors for AGEs and toll-like receptor 4 (TLR4). Protein glycation results in irreversible AGEs through a complicated series of reactions involving the formation of Schiff’s base, the Amadori reaction, followed by the Maillard reaction, which causes abnormal brain glucose metabolism, oxidative stress, malfunctioning mitochondria, plaque deposition, and neuronal death. Amyloid plaque and other stimuli activate macrophages, which are crucial immune cells in AD development, triggering the production of inflammatory molecules and contributing to the disease’s pathogenesis. The risk of AD is doubled by risk factors for atherosclerosis, dementia, advanced age, and type 2 diabetic mellitus (DM). As individuals age, the prevalence of neurological illnesses such as AD increases due to a decrease in glyoxalase levels and an increase in AGE accumulation. Insulin’s role in proteostasis influences hallmarks of AD-like tau phosphorylation and amyloid β peptide clearance, affecting lipid metabolism, inflammation, vasoreactivity, and vascular function. The high-mobility group box 1 (HMGB1) protein, a key initiator and activator of a neuroinflammatory response, has been linked to the development of neurodegenerative diseases such as AD. The TLR4 inhibitor was found to improve memory and learning impairment and decrease Aβ build-up. Therapeutic research into anti-glycation agents, receptor for advanced glycation end products (RAGE) inhibitors, and AGE breakers offers hope for intervention strategies. Dietary and lifestyle modifications can also slow AD progression. Newer therapeutic approaches targeting AGE-related pathways are needed.

Biomarkers are small molecules of interest to researchers, because they can indicate underlying diseases, often even before symptoms even appear. However, detecting these markers can be challenging as they are often present in very low quantities, especially in the early stages of a disease. Traditional detection methods, while effective, usually require expensive components like prisms, metal films, or optical objectives.

In a recent paper published in Applied Physics Letters, researchers at the University of Illinois Urbana-Champaign have unveiled a novel approach to detecting low concentrations of biomarkers that paves the way for biodetection technology that is simple to use, highly sensitive, and surprisingly affordable.

“The goal of this technology is early diagnostics, to be able to detect molecules associated with diseases at very low concentrations, sometimes a few molecules per millions, very early on,” said Seemesh Bhaskar, a postdoctoral researcher in Brian Cunningham’s lab and first author on the study. “Looking for very small concentrations of micro-RNA, circulating tumor DNA, and exosomes, for example, can help determine whether a patient will develop cancer one or two years down the line.”

Researchers at Cambridge have shown that the Third Thumb, a robotic prosthetic, can be quickly mastered by the public, enhancing manual dexterity. The study stresses the importance of inclusive design to ensure technologies benefit everyone, with significant findings on performance across different demographics.

Cambridge researchers demonstrated that people can rapidly learn to control a prosthetic extra thumb, known as a “third thumb,” and use it effectively to grasp and handle objects.

The team tested the robotic device on a diverse range of participants, which they say is essential for ensuring new technologies are inclusive and can work for everyone.

Cesarean section or C-section is a surgical procedure that delivers a baby through an abdominal incision. It is commonly used when the physicians believe it is a safer route for the parent, baby, or both. Cesarean section has appeared throughout history including Ancient Greece, India, Egypt, and Rome. There are even passages on cesarean section in different religious texts. It is believed that the name was attributed to the way Juluis Caesar was born. However, in Ancient Rome a cesarean section was only performed if at the time of birth, the mother was fatally ill and could not deliver naturally. It has been recorded that Julius Caesar’s mother was present during his life, therefore, historians believe he was not delivered through a cesarean section. Medical historians now believe the term originated from a decree in which Julius Caesar ordered women fated by birth to have a cesarean section which in Latin is “Caesones”. To this day, it is still incompletely understood where the name originated.

Cesarean sections are now routinely performed, and the procedure is well established. Interestingly, long-term effects of cesarean sections are not well known. Previously physicians noted no difference in health outcomes between children born through vaginal birth or cesarean section. Recently, however, a research group at the University of Cambridge found that a single dose of the measles vaccine is 2.6 times more likely to not be effective in children born through cesarean section. Unfortunately, a lack of vaccine efficacy leads to weakened immunity due to an inadequate number of antibodies produced to fight infection. While the first vaccination produced little efficacy, researchers demonstrated that a second measles vaccine was comparable to vaginally born children. More specifically, the vaccine was effective and produced the necessary antibodies to fight infection.

The recent paper published in Nature Microbiology by Dr. Henrik Salje, concluded the long-term effects of cesarean section delivery. Researchers suggest an increased risk of measles outbreak among children that were born through cesarean section and had only one measles vaccination. Salje and others explain that lack of vaccine efficacy is linked to the infants’ gut microbiome. It is well established that children receive great exposure to healthy microbes through vaginal birth, which boosts their immune systems. By avoiding microbe exposure through cesarean section, the infant loses critical immune protection.

Maj. Gen. Dr. Paul Friedrichs, MD is the Inaugural Director of the Office of Pandemic Preparedness and Response Policy, at the White House (OPPR — https://www.whitehouse.gov/oppr/), a permanent executive office aimed at leading, coordinating, and implementing actions to prepare for and respond to pathogens that could lead to a pandemic or significant public health-related disruptions in the U.S., and principal advisor on pandemic preparedness and response, appointed by President Biden.

Dr. Friedrichs was previously the Joint Staff Surgeon at the Pentagon where he provided medical advice to the Chairman of the Joint Chiefs of Staff, the Joint Staff and the Combatant Commanders, coordinating all issues related to health services, including operational medicine, force health protection and readiness among the combatant commands, the Office of the Secretary of Defense and the services. He also led the development and publication of the initial Joint Medical Estimate and served as medical advisor to the Department of Defense COVID-19 Task Force.

Continue reading “Dr Paul Friedrichs MD — Director, Office Of Pandemic Preparedness & Response Policy, The White House” »

Compared to open hemihepatectomy, the laparoscopic approach resulted in faster recovery time and higher quality of life, researchers found. Treatment with laparoscopic hemihepatectomy (resection, or surgical…

The UK’s National Health Service is fast-tracking patients for its new cancer vaccine trials that customize each jab to each patient.

For centuries, civilizations have used naturally occurring, inorganic materials for their perceived healing properties. Egyptians thought green copper ore helped eye inflammation, the Chinese used cinnabar for heartburn, and Native Americans used clay to reduce soreness and inflammation.

“The ORFAN study is an expanding global registry which will include long-term clinical and outcome data for 250,000 patients from around the world, and we are very pleased to publish these initial results,” said Keith Channon, MD, Professor of Cardiovascular Medicine at University of Oxford, Caristo Chief Medical Officer, and co-author of The Lancet publication.

“Coronary inflammation is a crucial piece of the puzzle in predicting heart attack risk. We are excited to discover that CaRi-Heart results performed exceptionally well in predicting patient cardiac events. This tool is well positioned to help clinicians identify high-risk patients with seemingly ‘normal’ CCTA scans.”

Ron Blankstein, MD, Professor of Medicine and Radiology at Harvard Medical School, Director of Cardiac Computed Tomography at Brigham and Women’s Hospital, and co-author of the publication, applauded The Lancet for publishing results from one of the largest studies in the field of CCTA.